Efficacy and pharmacoeconomical analysis of three platinum based chemotherapy regimens for advanced non small cell lung cancer
10.3760/cma.j.issn.1008-6706.2017.14.003
- VernacularTitle:三种含铂类化疗方案治疗晚期非小细胞肺癌的疗效和药物经济学分析
- Author:
Mengxi ZHANG
;
Wenjun YU
;
Chunling REN
;
Zheng JIAO
;
Zhijie AN
;
Dazhi WANG
- Keywords:
Carcinoma;
non-small-cell lung;
Cis-dichlorodamineplatinum;
Antineoplastic combined chemotherapy protocols;
Economics;
pharmaceutical
- From:Chinese Journal of Primary Medicine and Pharmacy
2017;24(14):2088-2091
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the cost-effectiveness and clinical effect of three platinum based chemotherapy regiments for advanced non small cell lung cancer (NSCLC).Methods 100 patients who were diagnosed as NSCLC,were randomly divided into four groups.The group Ⅰ received NP which was given NVB and DDP.The group Ⅱreceived GP which was given GEM and DDP.The group Ⅲ received TP which was given taxotere and DDP.The clinical effect,adverse reaction and cost effectiveness of the three groups were assessed.Results The clinical effective rates of the three groups were 31.43%,36.36%,37.50% from Ⅰ to Ⅲ group.The adverse events of the group Ⅰ and group Ⅱ were more than those of the group Ⅲ.In the adverse effects of treatment,the major cytotoxicity was digestive reaction and leukopenia in the two groups,but they were tolerable.The ratios of cost effectiveness in the four groups were 550.22yuan,556.48yuan,583.23yuan from Ⅰ to Ⅲ group.Conclusion The NP group is the best one in total cost.
